Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab

Authors

Rachel E. Sanborn, ProvidenceFollow
See all authors in comments

Document Type

Presentation

Publication Date

11-8-2022

Keywords

oregon; portland; chiles

Clinical Institute

Cancer

Department

Oncology

Comments

Sanborn R, Gabrail N, Carneiro B, O'Hara M, Bordoni R, Gordon M, Khalil D, Hauke R, Taglienti C, Rogalski M, Styles R, Alvarado D, Maurer D, Crew L, Keler T, Yellin M. SITC Annual Meeting; November 8-12; Boston, MA. 2022;10(Suppl 2): 596. doi: 10.1136/jitc-2022-SITC2022.0596.

Recommended Citation

Sanborn, Rachel E. and See all authors in comments, "Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab" (2022). Articles, Abstracts, and Reports. 6983.
https://digitalcommons.providence.org/publications/6983